Mumbai, August 13, 2025 – Medistep Healthcare Limited, a fast-growing player in the healthcare and medical device manufacturing sector, has successfully closed its Initial Public Offering (IPO), receiving an overwhelming response from investors across categories. The IPO was subscribed a remarkable 356.25 times, reflecting strong investor confidence in the company’s growth trajectory and future prospects.
The fixed-price issue of 37,44,000 equity shares at ₹43 per share, aggregating to a total issue size of ₹16.09 crore, witnessed bids for an impressive 1,33,38,15,000 shares.
Category-wise Subscription Details:
- Qualified Institutional Buyers (QIBs): 2,46,63,000 shares
- Non-Institutional Investors (NIIs): 48,90,18,000 shares
- Retail Individual Investors (RIIs): 82,01,34,000 shares
IPO Structure:
- Retail Investors Quota: Not less than 17,79,000 equity shares
- Non-Institutional Investors Quota: Not more than 17,76,000 equity shares
- Market Maker: 1,89,000 equity shares
The issue opened on August 8, 2025, and closed on August 12, 2025. The equity shares are set to be listed on August 18, 2025.
Company Overview & Use of Proceeds
Medistep Healthcare Limited plans to utilize the net proceeds from the IPO towards:
- Capital expenditure for the purchase of plant and machinery for expansion at its existing manufacturing facility
- Working capital requirements
- General corporate purposes
With the successful completion of the IPO, the company’s post-issue equity shares stand at 1,42,09,546, with a post-issue implied market capitalization of ₹61.10 crore.
IPO Details at a Glance:
- Face Value: ₹10 per share
- Issue Price: ₹43 per share
- Lot Size: 3,000 equity shares
- Pre-Issue Equity: 1,04,65,546 shares
- Post-Issue Equity: 1,42,09,546 shares
Issue Intermediaries:
- Lead Manager: Fast Track Finsec Private Limited
- Registrar: Cameo Corporate Services Limited
The extraordinary subscription numbers reflect strong market trust in Medistep Healthcare’s vision and execution capabilities. The company is well-positioned to enhance its manufacturing footprint and continue delivering quality healthcare solutions.